PubMed
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet
Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 47% · Mixed 34% · Unfavorable overall 19%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 295 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 49% · Mixed 42% · Unfavorable overall 9%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.025–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 35% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 27 days · Based on 402 repeat reporters
Published sources linked on the Larazotide and LL-37 wiki pages.
PubMed
Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015
PubMed
Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026
PubMed
Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016
PubMed
Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012
PubMed
Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024
PubMed
Soman D, P J, Cm M, et al. Archives of oral biology. 2026